This is the authors' abstract. We don't add key points for this paper.
Background : the drugs cariprazine and aripiprazole, from the group of third-generation antipsychotics, are recommended for both inpatient and outpatient treatment of schizophrenia, primarily to correct negative symptoms and minimize the risk of endocrine side effects caused by previous generations of drugs. The relevance of this study is due to the lack of research, including data from domestic psychiatric practice. The objectives of this research are to conduct a direct comparison of the effcacy and safety profiles of cariprazine and aripiprazole for the treatment of schizophrenia. Eliminating this information gap will undoubtedly contribute to optimizing the therapeutic process by personalizing the choice of antipsychotic medication. The aim of this study is to compare the therapeutic efficacy and safety of cariprazine versus aripiprazole during inpatient treatment for schizophrenia. Patients and Methods : an eight-week observational study was conducted at the V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology. Thirty-eight inpatient patients participated in the study, including 20 men and 18 women, aged 18 to 68 years, with a diagnosis of paranoid schizophrenia (F20.0) who had a positive response to therapy (at least a 30% reduction in total score on the Positive and Negative Syndrome Scale [PANSS]). Two groups of patients were formed based on monotherapy with atypical antipsychotics of the third generation: group I received cariprazine, and group II received Aripiprazole. Clinical and psychopathological assessments, psychometric measurements (PANSS and UKU scales), anthropometric measurements, and laboratory tests were conducted. Statistical analysis was also performed. Results: the analysis of psychometric indicators in dynamics showed that in both groups, there was a significant reduction in symptoms, as measured by the total PANSS score, by 14.0 (95% CI (2.2–25.8), p = 0.026) and 12.0 (95% CI (3.4–20.6), p = 0.013), in the first and second groups respectively. At the same time, among patients taking cariprazine, the decrease in negative symptoms on the PANSS subscale was statistically significant, amounting to – 4.3 points (95% CI (–9.3 — –0.3), p = 0.039). During 8 weeks of aripiprazole therapy, no significant changes in metabolic parameters were observed. In contrast, in the group of patients receiving cariprazine, a reduction in body weight of 1.8 kg (95% CI (1.3–2.3), p < 0.001) and a decrease in total fat percentage of –2.3% (95% CI (–3.3 — 1.3), p < 0.001) were observed. Conclusions: the results of this study suggest that cariprazine monotherapy may be more effective than aripiprazole for treating negative symptoms. Both, cariprazine and aripiprazole, have shown good tolerability and a low risk of side effects.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Иванов et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: